FDA clearance answers one question from one reviewer. Hospitals and payers ask different questions, and the evidence that answers them takes years to build.
Most MedTech companies build their clinical evidence strategy backward. They design the study that will clear the device, run it, collect the letter, and then discover that the hospital committee and the payer both want something the study was never built to produce.
The cost of that discovery is measured in years. A Stanford team publishing in JAMA Health Forum examined novel devices the FDA authorized between 2016 and 2019 that had no existing Medicare coverage. The median time to at least nominal coverage was 5.7 years, and 56% of the 64 technologies studied were still waiting as of early 2023.1
That gap is not mainly a paperwork problem. The FDA asked whether your device is substantially equivalent to something already on the market. Medicare asks whether it improves health outcomes for beneficiaries. A hospital asks whether it improves outcomes or cost compared with the product on its shelf. Three questions, three bodies of evidence, and usually one study.
The following post breaks down what clearance proves, what the other two audiences need instead, why the timing changed in 2026, and how to sequence evidence work so it arrives before the buying decision does.
A 510(k) clearance establishes that a device is substantially equivalent to a legally marketed predicate. It does not establish that the device is better than the alternative.
The FDA defines substantial equivalence as the same intended use as the predicate plus the same technological characteristics, or the same intended use with different characteristics that raise no new questions of safety and effectiveness. The agency describes a 510(k) as a submission demonstrating the device is "as safe and effective, that is, substantially equivalent, to a legally marketed device."2 The standard is relative, the reference point is a product that already exists, and devices are cleared rather than approved. Commercial copy should carry that distinction.
Clinical data is frequently not part of the package. FDA guidance states that "in many cases, a new device that is subject to 510(k) requirements can demonstrate SE to a predicate device through robust non-clinical safety and performance data, without the need for clinical data."3 That is a defensible regulatory standard and a thin commercial one. Bench testing that shows your device performs like its predicate tells a purchasing committee nothing about why it should switch.
Regulators, hospitals, and payers ask three different questions, and only the first is answered by the study that cleared you.
The FDA asks about equivalence and safety, and its comparator is a predicate device. The hospital asks about substitution, and its comparator is whatever is on the shelf today, measured in length of stay, complication and revision rates, procedure time, reprocessing cost, and total cost per case. The payer asks about a covered population against the current standard of care, measured in health outcomes, durability, and downstream utilization.
The comparator changes at every step, and a comparator cannot be added to a study after the study closes. If you want a hospital to see a cost-per-case difference, someone has to collect cost per case, prospectively, against the product that hospital uses today. Our value analysis committee post covers what that room asks for.
Under the RAPID coverage pathway, CMS posts a proposed national coverage determination on the day of FDA market authorization, which means the coverage evidence has to exist before the authorization does.
In August 2026, CMS published a notice establishing the Regulatory Alignment for Predictable and Immediate Device pathway. CMS states it will post a proposed national coverage determination on the day of FDA market authorization, with the goal of finalizing it as soon as 60 days later for Class II devices and 90 days later for Class III. Eligibility is narrow, covering certain Class II Breakthrough Devices in the FDA’s Total Product Life Cycle Advisory Program and Class III Breakthrough Devices planning a PMA. CMS paused the Transitional Coverage for Emerging Technologies pathway for new candidates in the same notice.4
For companies that qualify, the sequencing change is the whole story. CMS expects manufacturers to have tested whether the device improves health outcomes for Medicare beneficiaries, through investigational device exemption studies.4 That evidence cannot be assembled in 60 days. It has to be designed into the pivotal study years before anyone files.
Most companies will not qualify for RAPID, but the direction tells you what CMS considers a complete answer: beneficiary-level outcome data, collected under a protocol, available at authorization. Our reimbursement strategy post covers how coding, coverage, and payment fit around that.
Most post-market evidence programs fail because nobody owns them after the clearance letter arrives.
The clinical team disperses. Regulatory consultants are engaged through clearance, so six months later nobody left in the building can design a study.
Evidence sits in the wrong budget. Funded as a regulatory expense, it stops when the regulatory work stops, which is exactly when the commercial need begins.
The registry is built for complaints rather than claims. Post-market surveillance collects what quality needs, and it rarely carries a comparator, an economic endpoint, or a defined population.
Publication lag gets ignored. A study closing enrollment in month 18 reaches print around month 30 in a good case, and your first sales cycle needed it in month 6.
Evidence is a sequence of artifacts with different lead times, not a single study. Sorting the work by lead time rather than by importance is what makes the plan buildable.
Prospective comparative data with an economic endpoint, designed before the pivotal protocol locks, because the comparator and the endpoint are structural choices you cannot revisit later.
Single-site outcome series, retrospective chart review, registry enrollment, and time-and-motion studies, all of which can start the day the first unit ships.
The evidence dossier, meaning the existing literature on the clinical problem, the predicate class, and the cost of the current standard of care, organized into something a committee can read in twenty minutes and cite in its minutes.
The short-lead work is the piece most companies skip, and it is the only category available for the first committee meeting you will ever sit in. A dossier is not new evidence. It is the evidence that already exists, arranged to answer the question the room is asking rather than the question your pivotal study answered.
One constraint applies across all three tiers. Every claim has to trace back to a source and sit inside your cleared indication, because evidence supporting a use you are not cleared for is not evidence you can use. We build that discipline into the how we do it work from the start.
Real-world evidence can support a regulatory submission, but only when the underlying data was collected with that use in mind.
The FDA issued final guidance in December 2025 on real-world evidence for medical devices, superseding its 2017 version. The guidance turns on how the agency evaluates whether real-world data is of sufficient quality to generate real-world evidence.5 Registry data gathered without a protocol, a comparator, or a defined endpoint is a database, not evidence.
CMS runs a parallel mechanism. Coverage with Evidence Development pays only in the context of an approved clinical study, and CMS currently lists 27 national coverage determinations carrying a CED requirement.6 That is real coverage with a study attached, paid out of a commercial budget rather than a regulatory one.
A clinical evidence strategy is a plan for what evidence you will generate, in what order, for which audience. It covers the regulatory submission, the hospital purchasing decision, and the payer coverage decision, which each require different comparators and endpoints.
No. A 510(k) clearance means the FDA found the device substantially equivalent to a legally marketed predicate. It is a comparative finding about intended use and technological characteristics, not a determination that the device is safe, effective, or superior to alternatives.
It depends on the tier. A dossier built from existing literature takes weeks. A single-site outcome series takes roughly 9 to 18 months. Prospective comparative data with an economic endpoint generally takes 24 to 36 months, plus publication lag.
Sometimes, for specific questions. The FDA’s December 2025 guidance addresses how it evaluates whether real-world data has sufficient quality to generate usable evidence. Data collected without a protocol, a comparator, or a prespecified endpoint usually does not clear that bar.
Before the pivotal protocol locks. The comparator and endpoints a hospital or payer will need are structural choices, and adding them after a study opens is rarely possible.
A clinical evidence strategy is not a regulatory deliverable that happens to have commercial uses. It is a commercial asset that happens to start in the regulatory department.
The companies that get bought quickly after clearance decided, before the pivotal study locked, which comparator a hospital would demand and which endpoint a payer would count, then collected both. Everyone else spends two years after clearance building evidence while the sales team waits.
Decide what each audience needs, price the lead time, and start the long-lead work first.
Related reading: Post-Clearance Commercialization: Why the Work Has to Start Before Your Letter Arrives
Cicada is a MedTech launch partner that helps FDA-cleared companies bridge the gap between clearance and commercial success. Through market access messaging, KOL engagement programs, operational support, brand development, and precision-driven market expansion, Cicada aligns marketing, sales, and operations to build revenue-ready healthcare companies. Learn more at cicada.co or see how we do it.
1 Stanford Mussallem Center for Biodesign. "Stanford Researchers Study the Timelines from FDA Authorization to Medicare Approval." September 2023. https://med.stanford.edu/biodesign/our-impact/stories/stanford-researchers-study-the-timelines-from-fda-authorization-to-medicare-approval.html
2 U.S. Food and Drug Administration. "Premarket Notification 510(k)." https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
3 U.S. Food and Drug Administration. "Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions." September 2023. https://www.fda.gov/media/171837/download
4 Federal Register. "Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway." August 2026. https://www.federalregister.gov/documents/2026/08/11/2026-16368/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway
5 U.S. Food and Drug Administration. "Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices." December 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
6 Centers for Medicare & Medicaid Services. "Coverage with Evidence Development." August 2024. https://www.cms.gov/medicare/coverage/evidence
We work with commercially-viable health technology companies that are ready to scale. If that sounds like you, let's talk.
Schedule a Call